Zimmer Biomet Holdings Inc (ZBH) reported third-quarter earnings of $1.90 per share, slightly surpassing Wall Street's expectation of $1.89. Revenue for the quarter matched analyst forecasts at $2.0 billion.
The company will host an earnings conference call at BMO to discuss these results and provide additional insights on business performance.
This update provides insight into Zimmer Biomet's operational performance and financial health. Meeting analyst expectations indicates that business performance aligned with market forecasts. Investors are encouraged to review the full earnings release and listen to management commentary for complete context on the quarter's performance and future outlook.
Zimmer Biomet, headquartered in Warsaw, Indiana, designs, manufactures, and markets orthopedic reconstructive products. The company employs approximately 17,000 full-time employees and operates in segments including the Americas, EMEA, and Asia Pacific. Its products address disorders and injuries related to bones, joints, and supporting soft tissues. With a market cap of $17.54 billion and a P/E ratio of 21.31, Zimmer Biomet is positioned for continued growth in the health care sector. Upcoming earnings are scheduled for August 4, 2026, with an EPS estimate of $2.1486 and revenue forecast of $2.2 billion.